

What Advanced Practice Professionals Need to Know about Caring for Patients with Locally Advanced Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III PACIFIC trial evaluating durvalumab versus placebo after chemoradiation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC) demonstrated an improvement in which of the following outcomes with durvalumab?**
 - a. Only progression-free survival
 - b. Only overall survival
 - c. Both progression-free and overall survival**
- 2. In a prespecified analysis of the Phase III PACIFIC trial, durvalumab consolidation treatment demonstrated benefit for patients with locally advanced NSCLC and what level of PD-L1 expression?**
 - a. Low levels of PD-L1 expression only
 - b. High levels of PD-L1 expression only
 - c. All levels of PD-L1 expression**
- 3. Which of the following statements is true regarding the real-world incidence of pneumonitis in patients with locally advanced NSCLC in the HOPE-005/CRIMSON retrospective cohort study that evaluated pneumonitis/radiation pneumonitis after the FDA approval of durvalumab?**
 - a. The majority of cases of pneumonitis were symptomatic
 - b. The majority of cases of pneumonitis were asymptomatic**
- 4. Which of the following nonpneumonitis immune-mediated adverse events has been associated with durvalumab in the treatment of advanced NSCLC?**
 - a. Thyroid disorders
 - b. Rash
 - c. Diarrhea
 - d. Colitis
 - e. All of the above**
 - f. Only a, b and c